The antiangiogenic agent neovastat (Æ-941) inhibits vascular endothelial growth factor-mediated biological effects

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1242-1250

  Béliveau, Richard ^a   Gingras, Denis ^a   Kruger, Erwin A ^b   Lamy, Sylvie ^a   Sirois, Pierre ^c   Simard, Bryan ^c   Sirois, Martin G ^d   Tranqui, Leone ^e   Baffert, Fabienne ^e   Beaulieu, édith ^a   Dimitriadou, Violetta ^f   Pépin, Marie Claude ^f   Courial, Frank ^f   Ricard, Isabelle ^f   Poyet, Patrick ^f   Falardeau, Pierre ^f   Figg, William D ^b   Dupont, éric ^f  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF SHERBROOKE   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e CEA GRENOBLE   (France)

^f Les Laboratoires Æterna Inc 1405   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; BASIC FIBROBLAST GROWTH FACTOR; META TYROSINE; METALLOPROTEINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BINDING;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; CAPILLARIES; CAPILLARY PERMEABILITY; CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; LYMPHOKINES; PHOSPHORYLATION; PROTEIN BINDING; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TISSUE EXTRACTS; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036554985     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat. Med., 1: 149-153, 1995.
2. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
3. Brem, S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control, 6: 436-458, 1999.
4. Brem, H., and Folkman, J. Inhibition of tumor angiogenesis mediated by cartilage. J. Exp. Med., 141: 427-439, 1975.
5. Gingras, D., Renaud, A., Mousseau, N., and Béliveau, R. Shark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills? Cancer Metastasis Rev., 19: 83-86, 2000.
6. Moses, M. A., Sudhalter, J., and Langer, R. Identification of an inhibitor of neovascularization from cartilage. Science (Wash. DC), 248: 1408-1410, 1990.
7. Murray, J. B., Allison, K., Sudhalter, J., and Langer, R. Purification and partial amino acid sequence of bovine cartilage-derived collagenase inhibitor. J. Biol. Chem., 261: 4154-4159, 1986.
8. Moses, M. A., Wiederschain, D., Wu, I., Fernandez, C. A., Ghazizadeh, V., Lane, W. S., Flynn, E., Sytkowski, A., Tao, T., and Langer, R. Troponin I is present in human cartilage and inhibits angiogenesis. Proc. Natl. Acad. Sci. USA, 96: 2645-2650, 1999.
9. Sheu, J. R., Fu, C. C., Tsai, M. L., and Chung, W. J. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on antiangiogenesis and antitumor activities. Anticancer Res., 18: 4435-4441, 1998.
10. Liang, J. H., and Wong, K. P. The characterization of angiogenesis inhibitor from shark cartilage. Adv. Exp. Med. Biol., 476: 209-223, 2000.
11. Miller, R. R., and McDevitt, C. A. Thrombospondin is present in articular cartilage and is synthesized by articular chondrocytes. Biochem. Biophys. Res. Commun., 153: 708-714, 1988.
12. Liu, N., Lapcevich, R. K., Underhill, C. B., Han, Z., Gao, F., Swartz, G., Plum, S. M., Zhang, L., and Gree, S. J. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res., 61: 1022-1028, 2001.
13. Falardeau, P., Champagne, P., Poyet, P., Hariton, C., and Dupont, é. Æ-941 (Neovastat). a naturally occurring multifunctional antiangiogenic product in Phase III clinical trials. Semin. Oncol., 28: 620-625, 2001.
14. Batist, G., Patenaude, F., Champagne, P., Croteau, D., Levinton, C., Hariton, C., Escudier, B., and Dupont, é. Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a Phase II trial with two dose levels. Ann. Oncol., in press, 2002.
15. Dupont, é., Falardeau, P., Mousa, S. A., Dimitriadou, V., Pepin, M-C., Wang, T., and Alaoui-Jamali, M. A. Antiangiogenic and antimetastatic property of Æ-941. Clin. Exp. Metastasis. in press, 2002.
16. Castronovo, V., Dimitriadou, V., Savard, P., Rivière, M., and Dupont, E. Cartilage as a source of natural inhibitors of angiogenesis. In: B. A. Teicher (ed.), Antiangiogenic Agents in Cancer Therapy, pp. 175-183. Totowa, NJ: Humana Press, Inc., 1999.
17. Berger, F., Jourde, P., and Benabid, A-L. In vivo antitumoral activity of the multifunctional antiangiogenic agent Neovastat/Æ-941 in experimental glioma. Clin. Cancer Res., 6: 4520s, 2000.
18. Weber, M. H., Lee, J., and Orr, F. W. The effect of Neovastat (Æ-941) on an experimental metastatic bone tumor model. Int. J. Oncol., 20: 299-203, 2002.
19. Gingras, D., Renaud, A., Mousseau, N., Beaulieu, E., Kachra, Z., and Béliveau, R. Matrix proteinase inhibition by Æ-941, a multifunctional antiangiogenic compound. Anticancer Res., 21: 145-155, 2001.
20. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Wash. DC), 219: 983-985, 1983.
21. Larcher, F., Murillas, R., Bolontrade, M., Conti, C. J., and Jorcano, J. L. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability, and accelerated tumor development. Oncogene, 17: 303-311, 1998.
22. Kohn, S., Nagy, J. A., Dvorak, H. F., and Dvorak, A. M. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab. Investig., 67: 596-607, 1992.
23. Dvorak, A. M., and Feng, D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J. Histochem. Cytochem., 49: 419-432, 2001.
24. Connolly, D. T., Heuvelman, D. M., Nelson, R., Olander, J. V., Eppley, B. L., Delfino, J. J., Siegel, N. R., Leimgruber, R. M., and Feder, J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Investig., 84: 1470-1478, 1989.
25. Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N., Holash, J., McDonald, D. M., and Yancopoulos, G. D. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med., 6: 460-463, 2000.
26. Carmeliet. P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens. L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., and Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (Lond.), 380: 435-439, 1996.
27. Levy, A. P., Levy, N. S., and Goldberg, M. A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem., 271: 2746-2753, 1996.
28. Rak, J. W., St. Croix, B. D., and Kerbel, R. S. Consequences of angiogenesis for tumor progression, metastasis, and cancer therapy. Anti-Cancer Drugs, 6: 3-18, 1995.
29. Thomas, K. A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem., 271: 603-606, 1996.
30. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., and Heldin, C-H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem., 269: 26988-26995, 1994.
31. Guo, D., Jia, Q., Song, H. Y., Warren, R. S., and Donner, D. B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem., 270: 6729-6733, 1995.
32. Kroll, J., and Waltenberger, J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem., 272: 32521-32527, 1997.
33. Abedi, H., and Zachary, I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. 272: 15442-15451, 1997.
34. Gingras, D., Lamy, S., and Béliveau, R. Tyrosine phosphorylation of the vascular endothelial growth factor receptor-2 (VEGFR-2) is modulated by Rho proteins. Biochem. J., 348: 273-280, 2000.
35. Rousseau, S., Houle, F., Kotanides, H., Witte, L., Waltenberger, J., Landry, J., and Huot, J. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires the concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J. Biol. Chem., 275: 10661-10672, 2000.
36. Gerbert, H-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., and Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for FIk-1/KDR activation. J. Biol. Chem., 273: 30336-30343, 1998.
37. Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B., Zioncheck, T. F., Pelletier, N., and Ferrara, N. Analysis of biological effects and signaling properties of Flt-1 and KDR: a reassessment using novel highly receptor-specific VEGF mutants. J. Biol. Chem., 276: 3222-3230, 2001.
38. Dupont, E., Brazeau, P., and Juneau, C. Extracts of shark cartilage having an antiangiogenic activity and an effect on tumor regression; process of making thereof. United States Patent 5,618,925. Washington, DC: Government Printing Office, 1997.
39. Bernatchez, P. N., Soker, S., and Sirois, M. G. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J. Biol. Chem., 274: 31047-31054, 1999.
40. Bauer, K. S., Cude, K. J., Dixon, S. C., Kruger, E. A., and Figg, W. D. Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. J. Pharmacol. Exp. Ther., 292: 31-37, 2000.
41. Jaffé, E. A., Nachman, A. R. L., Becker, C. G., and Minick, C. R. Culture of human endothelial cells derived from umbilical veins. Identification of morphologic and immunologic criteria. J. Clin. Investig., 52: 2745-2756, 1973.
42. Keckwick, R. A., McKay, M. E., Nance, M. H., and Record, B. R. The purification of human fibrinogen. Biochem. J., 60: 671-683, 1955.
43. 3 integrin localization. In Vitro Cell. Dev. Biol., 33: 769-773, 1997.
44. Vailhé, B., Ronot, X., Lecomte, M., Wiernsperger, N., and Tranqui, L. Description of an in vitro model designed to test antiangiogenic molecules. Cell Biol. Toxicol., 12: 341-344, 1996.
45. Baffert, F., Usson, Y., and Tranqui, L. Effect of prolonged exposure to hypoxia on morphological changes of endothelial cells plated on fibrin gel. Eur. J. Cell Biol., 80: 78-86, 2001.
46. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak. A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular permeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
47. Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T., and Risau, W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell Biol., 140: 947-959, 1998.
48. Cross, M. J., and Claesson-Welsh, L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses, and therapeutic inhibition. Trends Pharmacol. Sci., 22: 201-207, 2001.
49. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
50. Claesson-Welsh, L., Welsh, M., Ito, N., Anand-Apte, B., Soker, S., Zetter, B., O'Reilly, M., and Folkman, J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA, 95: 5579-5583, 1998.
51. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
52. Taddei, L., Chiarugi, P., Brogelli, L., Cirri, P., Magnelli, L., Raugei, G., Ziche, M., Granger, H. J., Chiarugi, V., and Ramponi, G. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem. Biophys. Res. Commun., 263: 340-345, 1999.
53. O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S., and Folkman, J. Antiangiogenic activity of the cleaved conformation of the serpin anti-thrombin. Science (Wash. DC), 285: 1926-1928, 1999.
54. Kumar, R., and Yarmand-Bagheri, R. The role of HER2 in angiogenesis. Semin. Oncol., 28: 27-32, 2001.
55. Weng, D. E., and Usman, N. Angiozyme: a novel angiogenesis inhibitor. Curr. Oncol. Rep., 3: 141-146, 2001.
56. Laird, A. D., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., Fong, T. A., Strawn, L. M., Sun, L., Tang, C., Hawtin, R., Tang, F., Shenoy, N., Hirth, K. P., McMahon, G., and Cherrington, J. M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res., 60: 4152-4160, 2000.
57. Shaheen, R. M., Ahmad, S. A., Liu, W., Reinmuth, N., Jung, Y. D., Tseng, W. W., Drazan, K. E., Bucana, C. D., Hicklin, D. J., and Ellis, L. M. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer, 85: 584-589, 2001.
58. Mendel, D. B., Laird, A. D., Smolich, B. D., Blake, R. A., Liang, C., Hannah, A. L., Shaheen, R. M., Ellis, L. M., Weitman, S., Shawyer, L. K., and Cherrington, J. M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent. Anticancer Drug Des., 15: 29-41, 2000.
59. Kruger, E. A., Duray, P. H., Tsokos, M. G., Venzon, D. J., Libutti, S. K., Dixon, S. C., Rudek, M. A., Pluda, J., Allegra, C., and Figg, W. D. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem. Biophys. Res. Commun., 268: 183-191, 2000.
60. Berger, A. C., Alexander, H. R., Tang, G., Wu, P. S., Hewitt, S. M., Turner, E., Kruger, E., Figg, W. D., Grove, A., Kohn, E., Stern, D., and Libutti, S. K. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc. Res., 60: 70-80, 2000.
61. Bauer, K. S., Dixon, S. C., and Figg, W. D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol., 55: 1827-1834, 1998.
62. Hiraoka, N., Allen, E., Appel, I. J., Gyetko, M. R., and Weiss, S. J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell, 95: 365-377, 1998.
63. Sirois, M. G., and Edelman, E. R. VEGF effects on vascular permeability is mediated by synthesis of platelet-activating factor. Am. J. Physiol., 272: H2746-H2756, 1997.
64. Hofman, P., Blaauwgeers, H. G., Tolentino, M. J., Adamis, A. P., Nunes Cardozo, B. J., Vrensen, G. F., and Schlingemann, R. O. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr. Eye Res., 21: 637-645, 2000.
65. Roberts, W. G., and Palade, G. E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci., 108: 2369-2379, 1995.
66. Senger, D. R., Connolly, D. T., Van de Water, L., Feder, J., and Dvorak, H. F. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res., 50: 1774-1778, 1990.
67. Feng, D., Nagy, J. A., Hipp, J., Dvorak, H. F., and Dvorak, A. M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J. Exp. Med., 183: 1981-1986, 1996.
68. Murohara, T., Horowitz, J. R., Silver, M., Tsurumi, Y., Chen, D., Sullivan, A., and Isner, J. M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation, 97: 99-107, 1998.
69. Van Der Groot, H., and Timmerman, H. Selective ligands as tools to study histamine receptors. Eur. J. Med. Chem., 35: 5-20, 2000.
70. Ehringer, W. D., Edwards, M. J., and Miller, F. N. Mechanisms of α-thrombin, histamine, and bradykinin-induced endothelial permeability. J. Cell. Physiol., 167: 562-569, 1996.
71. Williams, T. J., Brain, S. D., Hellewell, P. G., Jose, P. J., Nourshargh, S., and Rampart, M. Alteration in microvascular permeability induced by products released during inflammation. In: C. L. Armour and J. L. Black (eds.), Mechanisms in Asthma: Pharmacology, Physiology, and Management, pp. 55-69. New York: A. R. Liss, 1988.
72. Regoli, D., and Barabe, J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev., 32: 1-46, 1980.
73. Mendel, D. B., Schreck, R. E., West, D. C., Li, G., Strawn, L. M., Tanciongco, S. S., Vasile, S., Shawver, L. K., and Cherrington, J. M., The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res., 6: 4848-4858, 2000.
74. Brekken, R. A., Overholser, J. P., Stastny V. A., Waltenberger, J., Minna, J. D., and Thorpe, P. E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res., 60: 5117-5124, 2000.
75. Tan, D. C., Kini, R. M., Jois, S. D., Lim, D. K., Xin, L., and Ge, R. A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett., 494: 150-156, 2001.